- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07951138
A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Three-Period, Six-Sequence Crossover Study in Healthy Volunteers to Compare the Relative Bioavailability of Itraconazole Tablet (T26) and Itraconazole Capsule (Sporanox®) Under Fed Conditions and to Assess the Food Effect on T26
This is a phase 1, randomized, open-label, single-center, single-dose, three-period, six-sequence crossover study in healthy adult volunteers. The study is designed to compare the relative bioavailability of itraconazole tablet (T26, Test) with itraconazole capsule (Sporanox®, Reference) under fed conditions; and to assess the food effect from a high-fat meal on T26.
Three treatments, as described below, are planned:
Test Product (Tfed): T26, 130 mg (two 65 mg tablets), administered under fed conditions Reference Product (R): Sporanox®, 200 mg (two 100 mg capsules), administered under fed conditions Test Product (Tfasted): T26, 130 mg (two 65 mg tablets), administered under fasted conditions A total of 18 participants will be randomized 1:1:1:1:1:1 into six different treatment sequences (TfastTfedR, TfastRTfed, TfedTfastR, TfedRTfast, RTfastTfed, RTfedTfast). The dosing between two consecutive treatment periods will be separated by a minimum 14-day washout interval.
This study consists of three periods: a screening period (Day -7~Day -2), a cross-over treatment period, and a safety follow-up visit (Day 36 ~Day 43). During each treatment period, eligible participants will be admitted to the clinical research unit (CRU) one day prior to dosing and will receive a single oral dose of the assigned study treatment on Day 1 according to the randomized sequence. On Day 1 of each treatment period, T26 or Sporanox® will be administered with 240 mL of water at approximately 8:00 a.m. (±1 hour) under fasted or fed condition. Detailed dietary requirements and dosing procedures. Participants will discharge from the CRU on the fifth day of each treatment period after completion of the scheduled safety assessments and collection of the last PK blood sample (up to 96 hours post-dose).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Junya Yu
- Telefoonnummer: 18752010068
- E-mail: yujunya@triastek.com
Studie Locaties
-
-
NA, Municipality
-
Chongqing, NA, Municipality, China, 400020
- No. 1, Jialing Yicun, Liangjiang New Area, Chongqing
-
Contact:
- Liangying Liu
- Telefoonnummer: +86-13436012840
- E-mail: 37145266@qq.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Healthy male and female participants aged 18 years and above (including 18 years).
-
Male participants with body weight ≥50.0 kg and female participants with body weight ≥45.0 kg. Body Mass Index (BMI) = weight (kg) / height² (m²), within the range of 18.5-30.0 kg/m² (inclusive).
-
Participants with no history of chronic or serious diseases of the cardiovascular, digestive, urinary, respiratory, hematologic/lymphatic, endocrine, immune, psychiatric, or nervous systems, and in good general health.
-
Participants must be willing to use effective contraception from screening until 2 months after the last dose of the final treatment cycle.
a) Female participants must: i. Be of non-child-bearing potential i.e. surgically sterilized or postmenopausal, or ii. If of child-bearing potential, must have a negative pregnancy test at Screening and within 24 hours prior to treatment Day 1. They must agree not to attempt to become pregnant, must not donate ova, and must agree to use two forms of highly effective contraceptive method between signing consent, during the study, and at least 2 months after the last dose of study drug, OR use 1 form of highly effective contraceptive method, plus an additional barrier method of contraception between signing consent, during the study, and at least 2 months after the last dose of study drug.
iii. Women of childbearing potential (WCBP) with same sex partners who abstain from penile- vaginal intercourse are eligible if such is their preferred and usual lifestyle.
c) Male participants must: i. Be willing not to donate sperm until at least 2 months after the last dose of study drug and.
ii. If engaging in sexual intercourse with a female partner who could become pregnant, be willing to use a condom in addition to having the female partner use a highly effective contraceptive method between signing consent, during the study, and at least 2 months after the last dose of study drug.
-
Voluntarily sign an informed consent form prior to the trial, with full understanding of the trial content, procedures, and potential adverse reactions, and be able to communicate effectively with investigators.
-
Capable of completing the study in accordance with the trial protocol requirements.
Exclusion Criteria:
- Vital signs, physical examination, hearing assessment, laboratory tests (hematology, urinalysis, blood chemistry, coagulation panel), infectious disease panel, 12-lead ECG, etc., showing clinically significant abnormalities;
- (Inquiry) Smoking 5 or more cigarettes per day on average within 3 months prior to screening, or unable to refrain from using any tobacco product within 48 h prior to administration and during hospitalization;
- (Inquiry) History of acute infectious disease with significant antibiotic use within 3 months before screening, or mild infectious disease within 7 days before first dose;
- (Inquiry) History of allergy to itraconazole, other azoles, or any excipients of the investigational product, or allergy to two or more substances;
- (Inquiry) Alcohol consumption >14 units per week within 3 months before screening (1 unit = 17.7 mL ethanol, equivalent to ~354 mL of 5% beer, ~44 mL of 40% spirits, or ~147 mL of 12% wine), or unable to abstain from alcohol-containing products during the study, or positive alcohol breath test;
- (Inquiry) Received blood transfusion, donated blood, or experienced major blood loss (≥400 mL) within 3 months before first dose;
- (Inquiry) Vaccinated within 14 days before first dose, or planning vaccination during the study period;
- (Inquiry) Taken any prescription medication, over-the-counter medication, vitamin products, or herbal supplements within 2 weeks before first dose;
- (Inquiry) Participants who, within 72 hours prior to the first dose, have consumed special diet (including dragon fruit, mango, grapefruit, etc.), or consumed foods or beverages containing caffeine or rich in xanthine (such as chocolate, strong tea, coffee, cola, animal offal), engaged in vigorous exercise, or have other factors affecting drug absorption, distribution, metabolism, or excretion;
- (Inquiry + System Search) Used other investigational products or participated in clinical drug trials within 3 months before first dose;
- Experienced acute illness or required concomitant medication from screening until first dose;
- Female participants who are breastfeeding or have a positive pregnancy test results at screening or during the study period;
- History of drug abuse within the past year, or illicit drug use within 3 months before screening, or positive drug abuse screening test;
- (Inquiry) Dysphagia, lactose intolerance (e.g., history of diarrhea after milk consumption), or inability to comply with standardized diet;
- (Inquiry) History of diseases that may affect safety or pharmacokinetics of the investigational product, such as gastric spasms, gastroesophageal reflux disease, Crohn's disease, chronic atrophic gastritis, Sjögren's syndrome, pernicious anemia, etc., or currently having any of these conditions;
- (Inquiry) Post-partial gastrectomy, or major surgery within 6 months before screening, or planning surgery during the study, or history of surgery affecting drug absorption, distribution, metabolism, or excretion (except appendectomy);
- (Inquiry + System Search) History of serious conditions judged by the investigator as clinically significant in the cardiovascular system (including congestive heart failure, coronary atherosclerotic heart disease, valvular heart disease, arrhythmia, torsades de pointes), hepatic system (active liver disease), urinary system, digestive system, respiratory system (including chronic obstructive pulmonary disease, cystic fibrosis), hematologic/lymphatic system (e.g., neutropenia), nervous system, psychiatric system, visual disorders/abnormalities, auditory disorders (including tinnitus and sudden deafness), malignant tumors, or currently having any of these conditions;
- (Inquiry) Use of any drugs known to interact with itraconazole within 4 weeks before screening [including methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (e.g., dihydroergotamine, ergometrine, ergotamine, methylergometrine), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, levacetylmethadol (levomethadyl), halofantrine, astemizole, mizolastine, terfenadine, sertindole, bepridil, lercanidipine, ivabradine, domperidone, colchicine, fesoterodine, telithromycin, solifenacin, erythromycin, clarithromycin, etc.];
- (Inquiry) Female participants who have used long-acting estrogen or progestogen injections or implants within 6 months before the study, or short-acting contraceptives within 30 days before the study;
- (Inquiry) History of vasovagal syncope from blood or needles, or unable to tolerate venipuncture;
- Participants unable to complete the study due to other reasons;
- Participants judged by the investigator to have other factors unsuitable for participation in this study;
- Participants with creatinine clearance <80 mL/min (calculated using Cockcroft-Gault formula: CrCl = [(140 - age) × weight (kg)] / [0.818 × serum creatinine (μmol/L)]; for females, multiply result by 0.85);
- (Inquiry) Participants with decreased gastric acidity, such as participants taking gastric acid secretion suppressors (e.g., H₂-receptor antagonists, proton pump inhibitors) or participants with achlorhydria caused by certain diseases.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Tfasted-Tfed-R group
|
Test Product Reference Product |
|
Experimenteel: Tfasted-R-Tfed group
|
Test Product Reference Product |
|
Experimenteel: Tfed-Tfasted-R group
|
Test Product Reference Product |
|
Experimenteel: Tfed-R-Tfasted group
|
Test Product Reference Product |
|
Experimenteel: R-Tfasted-Tfed group
|
Test Product Reference Product |
|
Experimenteel: R-Tfed-Tfasted group
|
Test Product Reference Product |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Cmax
Tijdsspanne: up to 96 hours post-dose
|
Primary PK parameters |
up to 96 hours post-dose
|
|
AUC0-tlast
Tijdsspanne: up to 96 hours post-dose
|
Primary PK parameters |
up to 96 hours post-dose
|
|
AUC0-inf
Tijdsspanne: up to 96 hours post-dose
|
Primary PK parameters |
up to 96 hours post-dose
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Tmax
Tijdsspanne: up to 96 hours post-dose
|
Secondary PK parameters |
up to 96 hours post-dose
|
|
t₁/₂
Tijdsspanne: up to 96 hours post-dose
|
Secondary PK parameters |
up to 96 hours post-dose
|
|
Kel
Tijdsspanne: up to 96 hours post-dose
|
Secondary PK parameters |
up to 96 hours post-dose
|
|
F
Tijdsspanne: up to 96 hours post-dose
|
Secondary PK parameters |
up to 96 hours post-dose
|
|
CL/F
Tijdsspanne: up to 96 hours post-dose
|
Secondary PK parameters |
up to 96 hours post-dose
|
|
Vz/F
Tijdsspanne: up to 96 hours post-dose
|
Secondary PK parameters |
up to 96 hours post-dose
|
|
AUC_%Extrap
Tijdsspanne: up to 96 hours post-dose
|
Secondary PK parameters |
up to 96 hours post-dose
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- T26-101
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .